Arikayce Posts 21% Greater Symptom Improvement in First-Line MAC Lung Trial

Insmed announced positive topline results from the Phase 3b ENCORE trial according to the company's press release Monday morning, clearing the way for Arikayce to expand from its current refractory niche into first-line treatment of MAC lung disease. The company plans to file a supplemental NDA in the second half of 2026.

This matters for a reason most people outside pulmonology don't appreciate: Mycobacterium avium complex lung disease is a slow, grinding infection with no great options. Patients cough for years. The standard antibiotic regimen — azithromycin plus ethambutol — converts cultures in about half of patients. The other half keep growing bacteria in their lungs, accumulating permanent damage.

ENCORE tested whether adding Arikayce (inhaled amikacin liposomes) to that standard regimen could improve the odds for newly diagnosed patients. The trial enrolled 425 patients across 177 sites globally, randomized to Arikayce plus multidrug therapy or placebo plus multidrug therapy for 12 months.

The Numbers

The primary endpoint was improvement in respiratory symptom score at month 13, using eight items from the Quality of Life – Bronchiectasis respiratory domain. Arikayce patients gained 17.77 points versus 14.66 for placebo — a statistically significant difference (p=0.0299), though the 3.11-point gap is modest enough that it will invite debate about clinical meaningfulness.

The culture conversion numbers are harder to argue with. By month 6, 87.8% of Arikayce patients had cleared their MAC infection versus 57% on placebo — a 30.8 percentage point difference (p<0.0001). Durable culture conversion at month 15, three months after stopping all treatment: 76.2% versus 47.6% (p<0.0001).

"These results are an exciting win for patients living with MAC lung disease," said Martina Flammer, Insmed's Chief Medical Officer. David Griffith, a steering committee member and professor at National Jewish Health, called them "groundbreaking," noting the potential to bring Arikayce earlier into the treatment journey.

What the Data Actually Says

The trial hit its primary endpoint and all multiplicity-controlled secondary endpoints except one: the PROMIS fatigue score at month 13 (p=0.2900). Patients on Arikayce were not significantly less tired than patients on placebo, despite clearing their infections at much higher rates. That disconnect — you're microbiologically cured but still exhausted — is worth watching as the drug moves toward broader use.

The safety profile was consistent with what's known about inhaled amikacin, which is to say: not trivial. Dysphonia (voice changes) hit 58.7% of Arikayce patients versus 8.5% on placebo. Cough was 32.9% versus 14.6%. Bronchospasm: 23%. The treatment discontinuation rate was 18.3% in the Arikayce arm versus 11.8% on placebo. These are real tolerability costs that patients and doctors will weigh against the substantial efficacy benefit.

No deaths were attributed to the drug. Serious adverse events were modestly higher in the Arikayce arm (14.1% vs 11.3%).

The Business Story

ENCORE fulfills the FDA's post-marketing requirement tied to Arikayce's 2018 accelerated approval for refractory MAC lung disease. Insmed will now seek traditional approval for that existing indication and label expansion into first-line treatment — a dramatically larger patient population.

The timing is good for Insmed. The company's first blockbuster, Brinsupri (brensocatib), won FDA approval in August 2025 as the first treatment for non-cystic fibrosis bronchiectasis. With Arikayce guided for $450–470 million in global revenue for 2026, a label expansion into first-line MAC could meaningfully accelerate that trajectory.

Insmed has built something unusual in biotech: a company with two late-stage respiratory assets addressing diseases that most pharma companies have ignored. MAC lung disease and bronchiectasis are both chronic, both underdiagnosed, and both lacked approved treatments for decades. The bet was that being the only company focused on these patients would eventually pay off. ENCORE suggests it is.

The sNDA filing and PMDA submission in Japan are planned for H2 2026. Full data presentation is expected at a future medical congress.